Molecular hydrogen is not a cancer treatment, and no credible research claims otherwise. What a growing body of early clinical research does examine is a narrower and more useful question: can hydrogen, taken alongside standard chemotherapy, radiotherapy, or immunotherapy, reduce treatment-related side effects or support immune function without interfering with the cancer treatment itself? This article reviews what that adjunctive-therapy research actually shows, separate from the radiation-specific quality-of-life research covered elsewhere on this site.
This article is for informational purposes only and is not a substitute for professional medical advice. Molecular hydrogen products have not been evaluated by the FDA to diagnose, treat, cure, or prevent any disease. Anyone undergoing cancer treatment should discuss any supplement, including hydrogen water or hydrogen inhalation, with their oncology team before starting.
Key Takeaways
- A randomized trial in colorectal cancer patients found hydrogen-rich water reduced chemotherapy-related liver enzyme elevations compared to placebo, without reported effects on chemotherapy efficacy [1].
- A small self-controlled study in advanced non-small cell lung cancer patients found two weeks of hydrogen inhalation normalized several markers of immune cell exhaustion and senescence [2].
- A single published case report described a lung cancer patient’s brain metastases resolving during hydrogen gas monotherapy; this is one patient’s outcome, not evidence hydrogen treats cancer [3].
- None of this research supports using hydrogen as a substitute for, or alternative to, standard oncology care.
The Liver-Protection Trial: The Strongest Evidence Here
The best-designed study in this space is a randomized, single-blind trial of 144 colorectal cancer patients undergoing mFOLFOX6 chemotherapy, a regimen known to be hard on the liver [1]. Patients were split into a hydrogen-rich water group and a placebo (distilled water) group, both drinking roughly a liter daily during treatment. Liver enzymes, ALT, AST, and bilirubin, are reliable, objective markers of chemotherapy-induced liver stress, and they rose significantly in the placebo group over the course of treatment while staying essentially unchanged in the hydrogen-rich water group. This is a genuinely well-controlled human RCT with a hard biochemical endpoint, not a subjective symptom score, which makes it the most convincing single study in the molecular hydrogen and cancer literature. It says something specific and useful: hydrogen-rich water may blunt one particular chemotherapy side effect. It does not say anything about tumor response or survival, because those weren’t what the trial measured.
Immune Function Research: Promising but Early
A separate line of research looks at whether hydrogen inhalation affects the immune system in cancer patients, since chemotherapy and the cancer itself can drive T cells into an exhausted or senescent state that responds poorly to treatment. A self-controlled study of 20 patients with advanced non-small cell lung cancer measured immune cell subsets before and after two weeks of daily hydrogen-oxygen gas inhalation (4 hours per day) during a treatment waiting period [2]. Several abnormal markers, including exhausted and senescent cytotoxic T cells, moved back toward normal ranges over the two-week period, and cell populations that started abnormally low, including natural killer cells, also increased.
This finding is interesting and mechanistically consistent with hydrogen’s proposed antioxidant activity, since chronic oxidative stress is one driver of T cell exhaustion. But the study design has real limits worth naming plainly: 20 patients, no control group, no placebo arm, and no cancer outcome measured, only immune cell counts. A self-controlled pre/post design like this cannot rule out the effect of simply resting during a treatment gap, and it says nothing about whether the immune changes translated into any clinical benefit for these particular patients.
The Case Report: What It Is and Isn’t
A single published case report describes a patient with non-small cell lung cancer and multiple brain metastases whose brain lesions resolved during a period of hydrogen gas monotherapy [3]. Case reports document one patient’s clinical course; they are useful for generating hypotheses and flagging something worth studying in a controlled trial, but a single favorable outcome in one person, without a control group, cannot separate the effect of hydrogen from every other variable in that patient’s care, disease biology, or spontaneous variation in tumor behavior. Citing a case report as if it were trial-level evidence is one of the most common ways supplement claims get overstated, and this site isn’t going to do that here: this is one data point, not proof of anything.
What This Does and Doesn’t Support
Reading across all three studies honestly: there is real, RCT-level evidence that hydrogen-rich water can reduce a specific, measurable chemotherapy side effect (liver enzyme elevation) in one cancer population. There is early, small-sample evidence that hydrogen inhalation shifts immune cell markers in a favorable direction in another cancer population, without proof this changes outcomes. And there is a single case report that generates a hypothesis but proves nothing about hydrogen’s effect on tumor behavior. None of this evidence supports hydrogen as a cancer treatment, a substitute for chemotherapy, radiotherapy, or immunotherapy, or a reason to delay or decline standard oncology care. The most defensible framing, consistent with how the liver-protection trial itself was designed, is as a possible adjunct to reduce specific treatment side effects, discussed with and monitored by an oncology team, not a self-directed alternative therapy.
Can hydrogen water interfere with chemotherapy working?
The available trials, including the liver-protection RCT, did not find evidence that hydrogen-rich water reduced chemotherapy’s antitumor effect; the concern in that trial was specifically about protecting liver tissue from a known chemotherapy side effect, not about blunting the treatment itself. That said, this is exactly the kind of question that needs to go to the treating oncologist for a patient’s specific regimen, since interaction data for every chemotherapy drug and every hydrogen delivery method does not exist.
Is hydrogen inhalation different from hydrogen water for these purposes?
Yes. The trials above use two different delivery methods, hydrogen-rich water for the liver-protection trial and inhaled hydrogen-oxygen gas mixture for the immune-marker study, and the doses and exposure times are not interchangeable. Neither method has been studied head-to-head for cancer-adjunctive purposes, so results from one shouldn’t be assumed to apply to the other.
References
- Protective effect of hydrogen-rich water on liver function of colorectal cancer patients treated with mFOLFOX6 chemotherapy. Mol Clin Oncol (2017). PMID 29142752
- Chen JB et al. Two Weeks of Hydrogen Inhalation Can Significantly Reverse Adaptive and Innate Immune System Senescence in Patients With Advanced Non-Small Cell Lung Cancer: A Self-Controlled Study. Med Gas Res (2020). PMID 33380580
- Brain Metastases Completely Disappear in Non-Small Cell Lung Cancer Using Hydrogen Gas Inhalation. Onco Targets Ther (2019). PMID 31908482
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
